{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T14:27:28Z","timestamp":1776436048709,"version":"3.51.2"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2010,4,1]],"date-time":"2010-04-01T00:00:00Z","timestamp":1270080000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2010,6]]},"DOI":"10.1007\/s00259-010-1439-8","type":"journal-article","created":{"date-parts":[[2010,3,31]],"date-time":"2010-03-31T08:48:37Z","timestamp":1270025317000},"page":"1124-1127","source":"Crossref","is-referenced-by-count":5,"title":["Key role of nuclear medicine in seeking biomarkers of Huntington\u2019s disease"],"prefix":"10.1007","volume":"37","author":[{"given":"Ferdinando","family":"Squitieri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Ciarmiello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,4,1]]},"reference":[{"key":"1439_CR1","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/0092-8674(93)90585-E","volume":"72","author":"No authors listed","year":"1993","unstructured":"A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington\u2019s disease chromosomes. The Huntington\u2019s Disease Collaborative Research Group. Cell 1993;72:971\u201383.","journal-title":"Cell"},{"key":"1439_CR2","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1093\/brain\/awg077","volume":"126","author":"F Squitieri","year":"2003","unstructured":"Squitieri F, Gellera C, Cannella M, Mariotti C, Cislaghi G, Rubinsztein DC, et al. Homozygosity for CAG mutation in Huntington disease is associated with a more severe clinical course. Brain 2003;126:946\u201355.","journal-title":"Brain"},{"key":"1439_CR3","unstructured":"Quarrell WJ, Brewer H, Squitieri F, Barker RA, Nance MA, Landwehrmeyer GB. Juvenile Huntington\u2019s disease and other trinucleotide repeat disorders. Oxford: Oxford University Press; 2009. p. 224."},{"key":"1439_CR4","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1212\/WNL.54.2.452","volume":"54","author":"K Marder","year":"2000","unstructured":"Marder K, Zhao H, Myers RH, Cudkowicz M, Kayson E, Kieburtz K, et al. Rate of functional decline in Huntington\u2019s disease. Huntington Study Group. Neurology 2000;54:452\u20138.","journal-title":"Neurology"},{"key":"1439_CR5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1755-5949.2008.00068.x","volume":"15","author":"F Squitieri","year":"2009","unstructured":"Squitieri F, Cannella M, Simonelli M, Sassone J, Martino T, Venditti E, et al. Distinct brain volume changes correlating with clinical stage, disease progression rate, mutation size, and age at onset prediction as early biomarkers of brain atrophy in Huntington\u2019s disease. CNS Neurosci Ther 2009;15:1\u201311.","journal-title":"CNS Neurosci Ther"},{"key":"1439_CR6","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1212\/WNL.44.8.1533","volume":"44","author":"No authors listed","year":"1994","unstructured":"Guidelines for the molecular genetics predictive test in Huntington\u2019s disease. International Huntington Association (IHA) and the World Federation of Neurology (WFN) Research Group on Huntington\u2019s Chorea. Neurology 1994;44:1533\u20136.","journal-title":"Neurology"},{"key":"1439_CR7","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1056\/NEJM199405193302001","volume":"330","author":"B Kremer","year":"1994","unstructured":"Kremer B, Goldberg P, Andrew SE, Theilmann J, Telenius H, Zeisler J, et al. A worldwide study of the Huntington\u2019s disease mutation. The sensitivity and specificity of measuring CAG repeats. N Engl J Med 1994;330:1401\u20136.","journal-title":"N Engl J Med"},{"key":"1439_CR8","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1093\/hmg\/3.12.2103","volume":"3","author":"F Squitieri","year":"1994","unstructured":"Squitieri F, Andrew SE, Goldberg YP, Kremer B, Spence N, Zeisler J, et al. DNA haplotype analysis of Huntington disease reveals clues to the origins and mechanisms of CAG expansion and reasons for geographic variations of prevalence. Hum Mol Genet 1994;3:2103\u201314.","journal-title":"Hum Mol Genet"},{"key":"1439_CR9","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1517\/14656566.8.2.141","volume":"8","author":"RM Bonelli","year":"2007","unstructured":"Bonelli RM, Hofmann P. A systematic review of the treatment studies in Huntington\u2019s disease since 1990. Expert Opin Pharmacother 2007;8:141\u201353.","journal-title":"Expert Opin Pharmacother"},{"key":"1439_CR10","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0092-8674(00)80623-6","volume":"101","author":"A Yamamoto","year":"2000","unstructured":"Yamamoto A, Lucas JJ, Hen R. Reversal of neuropathology and motor dysfunction in a conditional model of Huntington\u2019s disease. Cell 2000;101:57\u201366.","journal-title":"Cell"},{"key":"1439_CR11","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/mds.870050202","volume":"5","author":"JB Penney Jr","year":"1990","unstructured":"Penney Jr JB, Young AB, Shoulson I, Starosta-Rubenstein S, Snodgrass SR, Sanchez-Ramos J, et al. Huntington\u2019s disease in Venezuela: 7\u00a0years of follow-up on symptomatic and asymptomatic individuals. Mov Disord 1990;5:93\u20139.","journal-title":"Mov Disord"},{"key":"1439_CR12","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1002\/mds.870110204","volume":"11","author":"No authors listed","year":"1996","unstructured":"Unified Huntington\u2019s Disease Rating Scale: reliability and consistency. Huntington Study Group. Mov Disord 1996;11:136\u201342.","journal-title":"Mov Disord"},{"key":"1439_CR13","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/S1474-4422(09)70170-X","volume":"8","author":"SJ Tabrizi","year":"2009","unstructured":"Tabrizi SJ, Langbehn DR, Leavitt BR, Roos RA, Durr A, Craufurd D, et al. Biological and clinical manifestations of Huntington\u2019s disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. Lancet Neurol 2009;8:791\u2013801.","journal-title":"Lancet Neurol"},{"key":"1439_CR14","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/S1053-8119(02)00018-6","volume":"18","author":"M Quarantelli","year":"2003","unstructured":"Quarantelli M, Ciarmiello A, Morra VB, Orefice G, Larobina M, Lanzillo R, et al. Brain tissue volume changes in relapsing-remitting multiple sclerosis: correlation with lesion load. Neuroimage 2003;18:360\u20136.","journal-title":"Neuroimage"},{"key":"1439_CR15","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.expneurol.2008.12.026","volume":"216","author":"KE Weaver","year":"2009","unstructured":"Weaver KE, Richards TL, Liang O, Laurino MY, Samii A, Aylward EH. Longitudinal diffusion tensor imaging in Huntington\u2019s disease. Exp Neurol 2009;216:525\u20139.","journal-title":"Exp Neurol"},{"key":"1439_CR16","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1016\/j.neuroimage.2009.10.015","volume":"49","author":"HD Rosas","year":"2010","unstructured":"Rosas HD, Lee SY, Bender AC, Zaleta AK, Vangel M, Yu P, et al. Altered white matter microstructure in the corpus callosum in Huntington\u2019s disease: implications for cortical \u201cdisconnection\u201d. Neuroimage 2010;49:2995\u20133004.","journal-title":"Neuroimage"},{"key":"1439_CR17","first-page":"215","volume":"47","author":"A Ciarmiello","year":"2006","unstructured":"Ciarmiello A, Cannella M, Lastoria S, Simonelli M, Frati L, Rubinsztein DC, et al. Brain white-matter volume loss and glucose hypometabolism precede the clinical symptoms of Huntington\u2019s disease. J Nucl Med 2006;47:215\u201322.","journal-title":"J Nucl Med"},{"key":"1439_CR18","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1007\/s00259-009-1318-3","volume":"36","author":"I Carri\u00f3","year":"2009","unstructured":"Carri\u00f3 I. Key role of nuclear medicine in bringing imaging biomarkers into clinical practice. Eur J Nucl Med Mol Imaging 2009;36:1937\u20139.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"Pt 11","key":"1439_CR19","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1093\/brain\/awm217","volume":"130","author":"A Feigin","year":"2007","unstructured":"Feigin A, Tang C, Ma Y, Mattis P, Zgaljardic D, Guttman M, et al. Thalamic metabolism and symptom onset in preclinical Huntington\u2019s disease. Brain 2007;130(Pt 11):2858\u201367.","journal-title":"Brain"},{"key":"1439_CR20","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/S1474-4422(09)70178-4","volume":"8","author":"JM Burg van der","year":"2009","unstructured":"van der Burg JM, Bj\u00f6rkqvist M, Brundin P. Beyond the brain: widespread pathology in Huntington\u2019s disease. Lancet Neurol 2009;8:765\u201374.","journal-title":"Lancet Neurol"},{"key":"1439_CR21","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s00702-009-0328-4","volume":"117","author":"F Squitieri","year":"2010","unstructured":"Squitieri F, Falleni A, Cannella M, Orobello S, Fulceri F, Lenzi P, et al. Abnormal morphology of peripheral cell tissues from patients with Huntington disease. J Neural Transm 2010;117:77\u201383.","journal-title":"J Neural Transm"},{"issue":"Suppl 3","key":"1439_CR22","doi-asserted-by":"crossref","first-page":"S135","DOI":"10.1016\/S1353-8020(09)70800-4","volume":"15","author":"CA Ross","year":"2009","unstructured":"Ross CA, Shoulson I. Huntington disease: pathogenesis, biomarkers, and approaches to experimental therapeutics. Parkinsonism Relat Disord 2009;15 Suppl 3:S135\u20138.","journal-title":"Parkinsonism Relat Disord"},{"key":"1439_CR23","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/j.1399-0004.2004.00241.x","volume":"65","author":"DR Langbehn","year":"2004","unstructured":"Langbehn DR, Brinkman RR, Falush D, Paulsen JS, Hayden MR, International Huntington\u2019s Disease Collaborative Group. A new model for prediction of the age of onset and penetrance for Huntington\u2019s disease based on CAG length. Clin Genet 2004;65:267\u201377.","journal-title":"Clin Genet"},{"key":"1439_CR24","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1002\/cne.21272","volume":"501","author":"E Petrasch-Parwez","year":"2007","unstructured":"Petrasch-Parwez E, Nguyen HP, L\u00f6bbecke-Schumacher M, Habbes HW, Wieczorek S, Riess O, et al. Cellular and subcellular localization of Huntingtin [corrected] aggregates in the brain of a rat transgenic for Huntington disease. J Comp Neurol 2007;501:716\u201330.","journal-title":"J Comp Neurol"},{"key":"1439_CR25","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1093\/hmg\/ddp243","volume":"18","author":"RK Chaturvedi","year":"2009","unstructured":"Chaturvedi RK, Adhihetty P, Shukla S, Hennessy T, Calingasan N, Yang L, et al. Impaired PGC-1alpha function in muscle in Huntington\u2019s disease. Hum Mol Genet 2009;18:3048\u201365.","journal-title":"Hum Mol Genet"},{"issue":"36","key":"1439_CR26","doi-asserted-by":"crossref","first-page":"14424","DOI":"10.1073\/pnas.0703652104","volume":"104","author":"H Runne","year":"2007","unstructured":"Runne H, Kuhn A, Wild EJ, Pratyaksha W, Kristiansen M, Isaacs JD, et al. Analysis of potential transcriptomic biomarkers for Huntington\u2019s disease in peripheral blood. Proc Natl Acad Sci U S A 2007;104(36):14424\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1439_CR27","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1083\/jcb.200508072","volume":"171","author":"JY Shin","year":"2005","unstructured":"Shin JY, Fang ZH, Yu ZX, Wang CE, Li SH, Li XJ. Expression of mutant huntingtin in glial cells contributes to neuronal excitotoxicity. J Cell Biol 2005;171:1001\u201312.","journal-title":"J Cell Biol"},{"key":"1439_CR28","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1093\/brain\/awm044","volume":"130","author":"YF Tai","year":"2007","unstructured":"Tai YF, Pavese N, Gerhard A, Tabrizi SJ, Barker RA, Brooks DJ, et al. Microglial activation in presymptomatic Huntington\u2019s disease gene carriers. Brain 2007;130:1759\u201366.","journal-title":"Brain"},{"key":"1439_CR29","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.cell.2004.06.018","volume":"118","author":"LR Gauthier","year":"2004","unstructured":"Gauthier LR, Charrin BC, Borrell-Pag\u00e8s M, Dompierre JP, Rangone H, Cordeli\u00e8res FP, et al. Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules. Cell 2004;118:127\u201338.","journal-title":"Cell"},{"key":"1439_CR30","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1126\/science.1059581","volume":"293","author":"C Zuccato","year":"2001","unstructured":"Zuccato C, Ciammola A, Rigamonti D, Leavitt BR, Goffredo D, Conti L, et al. Loss of huntingtin-mediated BDNF gene transcription in Huntington\u2019s disease. Science 2001;293:493\u20138.","journal-title":"Science"},{"key":"1439_CR31","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1084\/jem.20080178","volume":"205","author":"M Bj\u00f6rkqvist","year":"2008","unstructured":"Bj\u00f6rkqvist M, Wild EJ, Thiele J, Silvestroni A, Andre R, Lahiri N, et al. A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington\u2019s disease. J Exp Med 2008;205:1869\u201377.","journal-title":"J Exp Med"},{"issue":"4","key":"1439_CR32","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1002\/ajmg.b.30501","volume":"144B","author":"A Ciammola","year":"2007","unstructured":"Ciammola A, Sassone J, Cannella M, Calza S, Poletti B, Frati L, et al. Low brain-derived neurotrophic factor (BDNF) levels in serum of Huntington\u2019s disease patients. Am J Med Genet B Neuropsychiatr Genet 2007;144B(4):574\u20137.","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"key":"1439_CR33","doi-asserted-by":"crossref","unstructured":"Battaglia G, Cannella M, Riozzi B, Orobello S, Maat-Schieman ML, Aronica E, et al. Early defect of transforming growth factor beta-1 formation in Huntington\u2019s disease. J Cell Mol Med 2010 Jan 15. [Epub ahead of print].","DOI":"10.1111\/j.1582-4934.2010.01011.x"},{"key":"1439_CR34","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1093\/brain\/awn025","volume":"131","author":"HD Rosas","year":"2008","unstructured":"Rosas HD, Salat DH, Lee SY, Zaleta AK, Pappu V, Fischl B, et al. Cerebral cortex and the clinical expression of Huntington\u2019s disease: complexity and heterogeneity. Brain 2008;131:1057\u201368.","journal-title":"Brain"},{"key":"1439_CR35","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1002\/ana.20121","volume":"55","author":"SA Reading","year":"2004","unstructured":"Reading SA, Dziorny AC, Peroutka LA, Schreiber M, Gourley LM, Yallapragada V, et al. Functional brain changes in presymptomatic Huntington\u2019s disease. Ann Neurol 2004;55:879\u201383.","journal-title":"Ann Neurol"},{"key":"1439_CR36","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1007\/s00259-009-1103-3","volume":"36","author":"F Squitieri","year":"2009","unstructured":"Squitieri F, Orobello S, Cannella M, Martino T, Romanelli P, Giovacchini G, et al. Riluzole protects Huntington disease patients from brain glucose hypometabolism and grey matter volume loss and increases production of neurotrophins. Eur J Nucl Med Mol Imaging 2009;36:1113\u201320.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1439_CR37","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.neulet.2005.09.037","volume":"393","author":"V Maglione","year":"2006","unstructured":"Maglione V, Cannella M, Martino T, De Blasi A, Frati L, Squitieri F. The platelet maximum number of A2A-receptor binding sites (Bmax) linearly correlates with age at onset and CAG repeat expansion in Huntington\u2019s disease patients with predominant chorea. Neurosci Lett 2006;393:27\u201330.","journal-title":"Neurosci Lett"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-010-1439-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00259-010-1439-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-010-1439-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,27]],"date-time":"2019-05-27T17:26:20Z","timestamp":1558977980000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00259-010-1439-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4,1]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010,6]]}},"alternative-id":["1439"],"URL":"https:\/\/doi.org\/10.1007\/s00259-010-1439-8","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,4,1]]}}}